Table 2. Comparison of baseline characteristics according to the status of early mycological clearance (success vs failure) among cases with HIV-associated CM in Peru*.
| Early mycological clearance | |||||
|---|---|---|---|---|---|
| Characteristics | N = 175 | Success (n = 77) | Failure (n = 98) | p | |
| Age—years | 175 | 33.5 ± 7.9 | 35.9 ± 9.7 | 0.076 | |
| CD4 load, n (%) | 137 | ||||
| <100 | 108 | 52 (78.8) | 56 (78.9) | 1.000 | |
| 100–199 | 20 | 10 (15.2) | 10 (14.1) | ||
| 200–499 | 9 | 4 (6.1) | 5 (7.0) | ||
| HIV load—copies log10/mL‡Δ | 113 | 4.5/54 ± 1.5 | 4.8/59 ± 1.3 | 0.190 | |
| Baseline CSF opening pressure—cmH2O§Δ | 165 | 27.3/74 ± 14.4 | 31.6/91 ± 12 | 0.040 | |
| Antiretroviral use, n (%) | 18/175 | 11 (14.3) | 7 (7.1) | 0.123 | |
| Previous episode of CM†, n (%) | 42/175 | 15 (19.5) | 27 (27.6) | 0.250 | |
| Antifungal treatment, n (%) | 175 | 0.050 | |||
| Amphotericin B | 109 | 44 (57.1) | 65 (66.3) | ||
| Amphotericin B plus fluconazol | 44 | 26 (33.8) | 18 (18.4) | ||
| Amphotericin B plus interferon | 22 | 7 (9.1) | 15 (15.3) | ||
| Frequency of serial lumbar punctures, n (%) | 170 | 0.047 | |||
| <4 | 92 | 47 (62.7) | 45 (47.4) | ||
| ≥4 | 78 | 28 (37.3) | 50 (52.6) | ||
| QCC—log10 CFU/mL¶Δ | 163 | 3.3/74 ± 1.2 | 3.9/89 ± 0.1 | 0.001 | |
| Cryptococcus growth rate, median (IQR)—daysΔ | 136 | 4/56 (2–6.5) | 3.5/80 (3–5) | 0.089 | |
| Treatment period, n(%)—years | 175 | 0.029 | |||
| 2000–2005 | 89 | 32 (41.2) | 57 (58.2) | ||
| ≥ 2006–2013 | 86 | 45 (58.4) | 41 (41.8) | ||
* Values represent the mean ± standard deviation unless otherwise specified.
Δ The values are from the number of samples tested.
† CM: cryptococcal meningitis.
‡ HIV load: number of HIV virus in blood.
§ CSF: cerebro spinal fluid.
¶ QCC: quantitative cryptococcal culture.